ZNF536 is a brain-specific zinc finger transcriptional repressor that negatively regulates neuronal differentiation 1. It binds to DNA sequences containing tandem 5'-AGGTCA-3' retinoic acid response elements (RARE) and competitively inhibits retinoic acid receptor alpha (RARA) binding, thereby suppressing retinoic acid-induced gene transcription 1. During neuronal differentiation, ZNF536 upregulation blocks neuron-specific marker gene expression, while its depletion or mutation enhances differentiation 1. ZNF536 also recognizes core DNA sequences 5'-CCCCCA-3' [UniProt summary]. Recent evidence demonstrates ZNF536's critical role in forebrain neuron development implicated in social behavior and stress responses 2, with dysregulation of retinoic acid-responsive gene networks and E2F4-mediated cell cycle pathways in knockout models 3. Genetically, ZNF536 variants are associated with schizophrenia risk 23 and represent de novo autism candidate mutations 4. Beyond neurodevelopment, ZNF536 alterations occur frequently in cancer, particularly lung adenocarcinoma and neuroblastoma, where elevated expression correlates with poor prognosis and promotes tumor progression through VEGFR2-PI3K-AKT pathway activation 56. ZNF536 expression predominantly localizes to brain tissues and endocrine tumors, with potential clinical applications as a neuroendocrine and immunotherapy biomarker.